knowledge -WSS

knowledge

author：focus 2025-10-02 13:40:45 - browse：87368

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Driven by the pandemic, applicants flood public health schools

Wikipedia

knowledge

WSS

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Medicare must police algorithms in Medicare Advantage, Dems say

Divers poised to search for children washed away in Pennsylvania flash flood

Hospitals struggle to profit from CAR

How to convince healthy people to buy insurance

Humans aren't the only ones with an imagination. Rats have it too

hotspot

knowledge

knowledge

The high cost of giving birth even with insurance

Driven by the pandemic, applicants flood public health schools

The cancer drug shortage isn’t new — and neither are the solutions

Awakening the world to the whoosh: A patient's crusade

Hepatitis C has a cure — but many Americans still lack access to it

7 more heat

How one medical school became remarkably diverse

Tocagen's brain cancer gene therapy trial continues. Investors worry

Cancer drug shortages should be causing more outrage

Stanford president faces new allegations over 1999 paper

focus

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Key Senate panel to consider PBM, drug pricing reform package

Indian pharmaceutical industry in denial over drug

Life sciences investors close nearly $6 billion in new funds

Lung cancer screening guidelines updated for cigarette smokers

Lung cancer screening guidelines updated for cigarette smokers

focus

Wikipedia

knowledge

explore